EIGHTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTAnd Option Agreement • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
SEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENT This SEVENTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTAnd Option Agreement • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
(this “Seventh Amendment”) is made and entered into as of January 5, 2022 (the “Seventh Amendment Effective Date”) between Sarepta Therapeutics Three LLC, a limited liability company organized and existing under the laws of the State of Delaware, United States of America, with its principal offices at 215 First Street, Cambridge, MA, 02142 (“Sarepta”) and F. Hoffmann-La Roche Ltd, a company organized and existing under the laws of Switzerland, with its principal office at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche”). Sarepta and Roche may be referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SAREPTA THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.License Agreement • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations
made and entered effective as of November 17, 2021 (the “Amendment No. 2 Effective Date”), by and between Sarepta Therapeutics, Inc., with offices at 215 First Street, Suite 415, Cambridge, MA 02142, USA and ST International Holdings Two, Inc. (the successor entity to Sarepta International C.V.), with a registered office at 251 Little Falls Drive, Wilmington, DE 19808, USA (collectively, “Sarepta”) on the one hand, and BioMarin Leiden Holding BV and its subsidiaries, BioMarin Nederlands BV and BioMarin Technologies BV (collectively, “BioMarin”), on the other hand. BioMarin and Sarepta may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the “Agreement”) by andSeparation Agreement and General Release • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
between Gilmore O’Neill (“Employee”) and Sarepta Therapeutics, Inc. (the “Company”), is made effective as of the date following Employee’s signature and the expiration of the seven (7) day revocation period without revocation (the “Effective Date”) with reference to the following facts:
SIXTH AMENDMENT TO LICENSE, COLLABORATION, AND OPTION AGREEMENTAnd Option Agreement • March 1st, 2022 • Sarepta Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Sarepta and Roche entered into that certain License, Collaboration, and Option Agreement executed on December 21, 2019 and effective as of February 4, 2020 and amended October 23, 2020,
